Palatin Technologies, Inc. (PTN) Stock Ticker
Market factors today
Unlock the full PTN picture
About Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
PTN stock facts
| Ticker symbol | PTN |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $18.0M |
| CEO | Carl Spana |
| Employees | 29 |
| Headquarters | Monmouth Junction, NJ, US |
| IPO date | 1997-10-15 |
| Website | palatin.com |
What you can see for PTN on Tickr
Live PTN price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PTN report.
Rankings
FAQ
What is the ticker symbol for Palatin Technologies, Inc.?
The ticker symbol for Palatin Technologies, Inc. is PTN, listed on the NASDAQ Capital Market.
What is PTN?
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial,…